key: cord-0747463-ftt4diu4
authors: Carreira, H.; Strongman, H.; Peppa, M.; McDonald, H. I.; dos-Santos-Silva, I.; Stanway, S.; Smeeth, L.; Bhaskaran, K.
title: Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: a matched cohort study using linked English electronic health records data
date: 2020-10-12
journal: nan
DOI: 10.1101/2020.10.08.20209304
sha: d1d0f861d0644ebb0e7b39bf101fd96ef2244af5
doc_id: 747463
cord_uid: ftt4diu4

Background People with active cancer are recognised as at risk of COVID-19 complications, but it is unclear whether the much larger population of cancer survivors is at elevated risk. We aimed to address this by comparing cancer survivors and cancer-free controls for (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of severe influenza, as a marker of susceptibility to severe outcomes from epidemic respiratory viruses. Methods We included survivors ([≥]1 year) of the 20 most common cancers, and age, sex and general practice-matched cancer-free controls, derived from UK primary care data linked to cancer registrations, hospital admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline demographics and comorbidities. Findings 108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer survivors had more asthma, other respiratory, cardiac, diabetes, neurological, renal, and liver disease, and less obesity, compared with controls, but there was variation by cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-29.35; HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR 2.22, 1.31-3.74). Interpretation Risks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This should be taken into account in policies targeted at clinical risk groups, and vaccination for both influenza, and, when available, COVID-19, should be encouraged in cancer survivors.

As of 7 July 2020, the novel Coronavirus disease 2019 has been 2 diagnosed in over 11.6 million individuals with more than 539,000 deaths reported 3 worldwide. 1 Around 20% of individuals contracting the virus are estimated to develop 4 severe disease requiring hospitalisation, with a high risk of mortality. 2 A key aspect of 5 managing the impacts of the pandemic is understanding who is vulnerable to 6 experiencing severe outcomes, so that mitigation strategies can be targeted at those 7 most in need. Those under current treatment for cancer were recognised early on as 8 being a high risk group, 3 but the extent to which the much larger population of medium-9 to long-term cancer survivors, might be considered vulnerable is unknown. In England 10 alone, this group includes over 1. 8 million people. 4 11 Current guidance on who should be considered vulnerable has been largely based on 12 policies developed for previous epidemic respiratory viruses, notably influenza. For 13 example, vaccination against influenza is only recommend for individuals under active 14 treatment for cancer and for up two years following some treatments and 15 haematological cancers, 5 while longer-term cancer survivors with no recent 16 immunosuppressing treatment are not considered high-risk in vaccination guidance 17 from Public Health England or the American Cancer Society. 5,6 Yet medium-to long-18 term cancer survivors could plausibly be at raised risk of severe COVID-19 outcomes.

Studies among women with breast cancer have found chemotherapy to be associated 20 with changes in immune parameters that did not return to pre-treatment levels a year 21 or more after end of treatment, raising the possibility of a long-term weakened immune 22 system in cancer survivors. 7, 8 In addition, cancer survivors have known raised risks of 23 heart disease, 9 which is itself an emerging risk factor for COVID-19 mortality. 10 One 24 large UK study identified raised risks of COVID-19 mortality in survivors of 25 haematological malignancies even several years after cancer diagnosis, 11 but there is 26 little other evidence to date to inform policy around managing COVID-19 related risks 27 in cancer survivors.

We therefore aimed to investigate whether cancer survivors are likely to be a high-risk 29 group for severe outcomes during the current COVID-19 pandemic in two ways: first, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020 . . https://doi.org/10.1101 /2020 linked data restricted our study to England and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209304 doi: medRxiv preprint 1 improved when the Quality and Outcomes Framework was introduced in 2004. 12 2 Cancer survivors were followed up from 1 year after diagnosis (index date) and 3 matched on age (±3 years), sex, and general practice to 5 controls with no history of 4 cancer and at least 2 years of follow-up prior to the index date of the matched cancer 5 survivor (since cancer survivors had to have one year of follow-up before and after the 6 date of cancer diagnosis to be included). Cancer survivors were eligible to be selected 7 as controls until the date of the incident cancer.

Outcome and covariates

The main outcome for the study was influenza hospitalisation or death, identified using 11 ICD-10 codes in HES and ICD-9 and ICD-10 codes in ONS mortality data (codes 12 available in Supplementary Table S1 ). For the primary analysis, we counted 13 hospitalisations with a primary diagnosis of influenza, and deaths with an underlying 14 cause of influenza. In a sensitivity analysis, we broadened the definition to include 15 hospitalisations/deaths with any code for influenza present.

Age and sex were matching factors. Other covariates were index of multiple 17 deprivation quintile, smoking status (never, former, current smoker), and common 18 comorbidities identified a priori as of potential importance in determining risk of severe 19 COVID-19 outcomes, namely asthma, chronic respiratory disease other than asthma, 20 chronic heart disease, chronic liver disease, chronic neurological disease, chronic 21 kidney disease, diabetes, obesity, sickle cell disease or splenectomy. Other causes of 22 immunosuppression were not included due to overlap with cancer and its treatment. In 23 a secondary analysis we also described the total number of comorbidities ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020 . . https://doi.org/10.1101 /2020 matching factors (i.e. age at index date, sex, and general practice) through stratification 7 by matched set and then additionally adjusting for the presence of risk factors at the 8 index date (for this analysis obesity was classified at the cancer diagnosis date since 9 weight measures in the year following cancer diagnosis may be unstable). We examined the role of time since cancer diagnosis, by fitting a time-updated variable 11 indicating time of cancer survivorship (1 to <5, 5 to <10, and ≥10 years since diagnosis, 12 vs control group patient).

Since haematological malignancies directly affect the immune system and treatments 14 may have long-term immune consequences, we stratified results by haematological 15 versus other cancers by fitting a three-level cancer survivorship variable. Due to limited 16 power, we did not break cancer sites down further. In a post hoc analysis, the exposure gastrointestinal, genitourinary, others); Wald tests were used after model estimation to 20 test the null hypothesis of heterogeneity of effect among subgroups.

As a secondary analysis, we explored mediation of any raised risk of the primary 22 outcome by development of recognised risk factors during follow-up, by adjusting for 23 time-updated risk factor variables (taking the value "0" until the risk factor is first 24 present, and "1" afterwards). This analysis was additionally censored at the end of 25 follow-up in CPRD GOLD, since it relies on post-baseline primary care data.

Patients with missing data on BMI, smoking or deprivation were excluded from the 27 cohorts (see above), therefore all models were based on complete case analyses.

Multiple imputation was not used, as the missingness was considered likely to be not 29 at random in the primary care setting 15,16 , and complete case analysis minimises bias 30 in this situation, providing missingness is conditionally independent of the outcome 31 17 .Sensitivity analyses: We conducted two main sensitivity analyses. First, we 32 broadened our definition of the outcome to include influenza recorded anywhere in the 33 hospitalisation or death record, to account for the possibility of differential prioritisation 34 of influenza codes between cancer survivors and controls. Second, we adjusted for is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209304 doi: medRxiv preprint healthcare, or vaccination indicated by immunosuppression following cancer and its 1 treatment, which may protect against influenza and influenza-related death from 2 secondary bacterial pneumonia. Influenza vaccinations were considered current from 3 the date of vaccination until the start of the following influenza season in September.

As vaccination records were ascertained from primary care data, these analyses were 5 additionally censored at the end of CPRD follow up; we also re-ran the primary model 6 with this additional censoring in order to provide a similarly censored comparator for 7 the sensitivity and mediation analysis models. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. cell/splenectomy not shown as the prevalence was <0.2% in all groups). At 5-years 10 after diagnosis, cancer survivors overall had slightly higher prevalence of all risk factors 11 except heart disease and neurological conditions (differences in prevalences ranging 12 from 0.3% for diabetes and chronic liver disease, to 1.8% for chronic kidney disease).

Survivors of most site-specific cancers also had raised prevalences of these risk 14 factors, with the magnitude varying by cancer site. The prevalence of obesity was lower 15 in cancer survivors than controls for several cancer sites, but was substantially more 16 common in survivors of uterus and kidney cancers (prevalence difference at 5 years the cancer survivors had at least 1 of the included comorbidities 5 years after 19 diagnosis, while 37.3% had two or more (Supplementary Table S2 ). Comorbidity 20 prevalences stratified by age and sex are provided in Supplementary Figure S2 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209304 doi: medRxiv preprint years from diagnosis respectively. Associations were smaller for non-haematological 1 cancer survivors. The overall adjusted HR was 1.38 but compatible with chance 2 variation (95%CI 0.92-2.07). However, stratification by time since diagnosis suggested 3 a doubling of risk in those 1 to <5 years from diagnosis (adjusted HR 2.22, 1.31-3.74) 4 with no raised risk in longer-term survivors.

Sensitivity, mediation and post-hoc analyses 7 Using hospitalisations and deaths with any mention of influenza in the outcome 8 definition led to more events being included (n=320) but a very similar pattern of results 9 to the primary analysis (Supplementary Table S3 ). In analyses that censored at end of 10 CPRD follow-up, fewer events were included (n=167) but hazard ratios were generally 11 larger than in the primary analysis (overall adjusted HR for cancer survivors vs controls is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. .

Most comorbidities thought to be risk factors for COVID-19 were more prevalent in 2 cancer survivors than cancer-free controls, with variation by cancer site. After 3 accounting for baseline demographics, deprivation, smoking and risk factors 4 distribution, the risks of influenza hospitalisation and death were elevated >9-fold in 5 haematological cancer survivors compared with matched controls for at least 10 years 6 after diagnosis, and >2-fold in non-haematological cancer survivors in the one to five 7 years after diagnosis.

To our knowledge, this is the first large cohort study using prospectively collected data 9 to quantify the relative risk of severe influenza outcomes in different groups of cancer is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209304 doi: medRxiv preprint previous malignancy, finding high 30-day mortality, even among those in remission, 1 though active disease was a strong predictor of mortality. 24 Finally, a study that 2 focussed on patients with active cancer and COVID-19 found a non-statistically 3 significant increased risk of mortality in patients exposed to chemotherapy 4 weeks 4 prior to infection (OR=1.18, 95%CI 0.81-1.72), compared to cancer patients that did 5 not receive chemotherapy, but the small numbers involved require further studies to 6 confirm these associations. 25

We used a large cohort of cancer survivors and matched controls, nearly a quarter of 8 whom were followed up for more than 10 years. The size of our study enabled us to 9 estimate prevalence of risk factors for severe respiratory infections in site-specific 10 cancer survivors for the twenty most common cancer sites with good precision, and to 11 adjust our primary analysis of severe influenza outcomes for multiple risk factors and 

There are some important limitations. We analysed severe influenza in an attempt to 21 inform COVID-19 policy but despite both being infectious respiratory illnesses, it is not 22 certain that risk factors for severe influenza will have the same associations with 23 COVID-19. Our approach follows that of policy makers who have assumed parallels 24 with influenza in the absence of mature COVID-19 data. 27 As data from the COVID-19 25 pandemic itself have started to flow, they have largely confirmed a broad overlap 26 between those at high risk for seasonal influenza and for severe COVID-19 27 outcomes. 11 Another limitation was that we did not have data on anti-cancer 28 treatments, so could not separate cancer survivors into those under active treatment 29 or not undergoing any treatment, which may be an important determinant of risk. We 30 only included cancer survivors at least one year out from diagnosis, so it is likely that 31 most patients with high-grade malignancies would have completed primary treatment, 32 but people with low-grade tumours could conceivably have received anticancer 33 therapies some years after initial diagnosis, which could explain part of the medium-34 to long-term increased risk of severe influenza; linked cancer treatment data will be 35 needed to investigate this further. We cannot rule out that differences in the prevalence 36 of risk factors between cancer survivors and controls five years post-diagnosis may be 37 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209304 doi: medRxiv preprint due to increased contact with health services, particularly for diseases such as chronic 1 kidney disease which may be asymptomatic. Our primary outcome combined influenza 2 hospitalisations and deaths but was dominated by the former; it is plausible that there 3 may be a lower threshold for hospitalisation in cancer survivors which could have 4 exaggerated the difference in risk of the primary outcome between cancer survivors 5 and controls, but is unlikely to fully explain the large associations we observed. Finally, 6 we had some missing data on smoking and BMI data, and we excluded those with 7 missing data from the analysis; this is unlikely to affect our findings under the 8 assumption that the association between cancer survivorship and severe respiratory 9 outcomes is the same in people with and without missing data, conditional on the 10 covariates included in the model. We have no reason to doubt this assumption, as 11 recording of BMI and smoking in primary care could be associated with cancer 

Our results also have implications for preventive medicine in the coming autumn and 28 winter, when influenza and SARS-CoV-2 are expected to coexist in the population.

Improving influenza vaccination coverage among cancer survivors should be a priority, 30 as the vaccine is both effective and safe 29,30 but coverage has been reported in the 31 range of 50% to 76% among cancer survivors in the US and in the UK. 31,32

Immunisation for streptococcus pneumoniae may also be considered. 33 Of note, UK is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . https://doi.org/10. 1101 /2020 Future studies should focus on the risk of severe COVID-19 in cancer survivors, 1 explore the role of comorbidities and prior exposure to specific anti-cancer therapies, 2 disaggregating data by cancer site when possible.

In conclusion, survivors of haematological malignancies had substantially elevated 4 risks of influenza hospitalisation or death persisting for at least 10 years after cancer 5 diagnosis, while risk was doubled for survivors of other cancers for up to 5 years from 6 diagnosis. In addition, cancer survivors had higher prevalence of several chronic 7 conditions associated with severe COVID-19, compared to people with no history of 8 cancer. This should be taken into account in public health policies targeted at 9 protecting clinical risk groups. Influenza vaccination should be encouraged in this 10 group, and may need to be extended to a wider population of medium-to long-term 11 cancer survivors than currently recommended. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020 . . https://doi.org/10.1101 /2020 List of tables 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted October 12, 2020. . https://doi.org/10.1101/2020.10.08.20209304 doi: medRxiv preprint 

Clinical course and mortality risk of severe COVID-19

Data Resource 8 Profile: Hospital Episode Statistics Admitted Patient Care (HES APC)

Data Resource Profile: National Cancer Registration Dataset in 12

This study is based in part on data from the Clinical Practice Research Datalink